Our market reports now include the latest updates on global tariffs, trade impacts, and evolving supply chain dynamics.
What is the current market size of the chemotherapy-induced neutropenia treatment industry, and what growth rate is it expected to achieve?
The chemotherapy-induced neutropenia treatment market size has grown strongly in recent years. It will grow from $0.59 billion in 2024 to $0.62 billion in 2025 at a compound annual growth rate (CAGR) of 5.7%. The growth in the historic period can be attributed to increasing cancer incidence rates, rising chemotherapy adoption, growing geriatric population, high hospitalization rates due to infections, and expanding oncology drug pipelines.
The chemotherapy-induced neutropenia treatment market size is expected to see strong growth in the next few years. It will grow to $0.76 billion in 2029 at a compound annual growth rate (CAGR) of 5.3%. The growth in the forecast period can be attributed to rising demand for targeted neutropenia therapies, growing investment in oncology research and development, increasing focus on outpatient care, expanding use of biosimilars, and increasing awareness of infection prevention. Major trends in the forecast period include development of long-acting granulocyte colony-stimulating factor therapy (G-CSF) agents, increasing use of combination therapies, rising preference for home-based care solutions, surge in biosimilar approvals, and integration of digital health monitoring tools.
Download Your Free Sample PDF:
https://www.thebusinessresearchcompany.com/sample.aspx?id=24190&type=smp
What are the major drivers contributing to the growth of the chemotherapy-induced neutropenia treatment market?
The increasing incidence of cancer is expected to propel the growth of the chemotherapy-induced neutropenia treatment market going forward. Cancer refers to a group of diseases characterized by the uncontrolled growth and spread of abnormal cells in the body. The rise in cancer cases is due to the aging population, as older individuals have a higher risk of developing cancer due to accumulated genetic mutations and weakened immune function over time. Chemotherapy-induced neutropenia treatment aids in cancer care by reducing infection risks through immune support, ensuring patients can continue chemotherapy with fewer interruptions. It enhances treatment outcomes by minimizing complications, thereby improving overall patient safety and quality of life. For instance, in July 2024, according to the Australian Institute of Health and Welfare, an Australia-based government agency, the number of cancer cases diagnosed in Australia rose to 160,570 in 2022, an increase of 3,789 cases from 156,781 in 2021. Therefore, the increasing incidence of cancer is driving the growth of the chemotherapy-induced neutropenia treatment market.
What are the major market segments driving the growth of the chemotherapy-induced neutropenia treatment industry?
The chemotherapy-induced neutropenia treatment market covered in this report is segmented –
1) By Type: Antibiotic Therapy, Granulocyte Colony-Stimulating Factor Therapy (G-CSF), Granulocyte Transfusion, Other Types
2) By Route of Administration: Subcutaneous, Intravenous
3) By Indication: Solid Tumors, Hematological Malignancies, Other Indications
4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
5) By End-User: Hospitals, Specialty Clinics, Homecare Settings
Subsegments:
1) By Antibiotic Therapy: Broad-Spectrum Antibiotics, Narrow-Spectrum Antibiotics, Prophylactic Antibiotics
2) By Granulocyte Colony-Stimulating Factor Therapy (G-CSF): Filgrastim, Pegfilgrastim, Lenograstim
3) By Granulocyte Transfusion: Allogeneic Granulocyte Transfusion, Autologous Granulocyte Transfusion
4) By Other Types: Antifungal Therapy, Stem Cell Therapy, Immunomodulatory Therapy
View The Full Market Report:
What are the key trends shaping the chemotherapy-induced neutropenia treatment market in the forecast period?
Major companies operating in the chemotherapy-induced neutropenia treatment market are focusing on developing innovative products and getting approvals, such as long-acting formulations to improve patient convenience, reduce dosing frequency, and enhance treatment adherence. Long-acting formulations refer to drug preparations designed to release active ingredients slowly over an extended period, reducing the frequency of administration. For instance, in December 2023, Coherus BioSciences Inc., a US-based biopharmaceutical company, received the U.S. Food and Drug Administration (FDA) approval for Udenyca Onbody, a novel, ready-to-use on-body injector. This device containing a long-acting formulation automatically delivers pegfilgrastim approximately 27 hours after chemotherapy, eliminating the need for a next-day injection. Udenyca Onbody enhances patient experience by ensuring timely prophylactic treatment of chemotherapy-induced neutropenia while reducing clinic visits and improving adherence.
Who are the key market players contributing to the growth of the chemotherapy-induced neutropenia treatment industry?
Major companies operating in the chemotherapy-induced neutropenia treatment market are Pfizer Inc., Johnson & Johnson, Merck & Co. Inc., GSK plc, Bristol-Myers Squibb Company, Novartis AG, Takeda Pharmaceutical Company Limited, Amgen Inc., Teva Pharmaceutical Industries Ltd., Astellas Pharma Inc., Biogen Inc., Baxter Inteational, Fresenius Kabi, Eisai Co. Ltd., Dr. Reddy’s Laboratories Ltd., Exelixis Inc., Biocon Biologics Limited, Coherus BioSciences Inc., G1 Therapeutics, Enzychem Lifesciences Corporation
Which regions are leading the growth of the chemotherapy-induced neutropenia treatment market globally?
North America was the largest region in the chemotherapy-induced neutropenia treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the chemotherapy-induced neutropenia treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
How Can Companies Use The Chemotherapy-Induced Neutropenia Treatment Market Report to Drive Business Results?
This report provides actionable insights tailored for business use—not academic analysis. Companies can leverage the data to:
• Time market entry or expansion using growth forecasts and CAGR trends.
• Develop competitive products by tracking key technology shifts and user preferences.
• Tailor regional strategies with in-depth geographic data and local market dynamics.
• Benchmark and plan partnerships using competitive landscape insights.
Purchase The Report And Get A Swift Delivery:
https://www.thebusinessresearchcompany.com/customise?id=24190&type=smp
Need Customized Data On Chemotherapy-Induced Neutropenia Treatment Market?
For companies needing more tailored intelligence, The Business Research Company offers customized consulting and data services. Whether you’re entering new regions, launching innovative products, or assessing M&A opportunities, our experts can develop actionable insights specific to your business objectives.
Request Customized Data:
https://www.thebusinessresearchcompany.com/sample.aspx?id=24190&type=smp
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
https://thebusinessresearchcompany.com/
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
